Peter C Enzinger

Peter C Enzinger

UNVERIFIED PROFILE

Are you Peter C Enzinger?   Register this Author

Register author
Peter C Enzinger

Peter C Enzinger

Publications by authors named "Peter C Enzinger"

Are you Peter C Enzinger?   Register this Author

63Publications

1718Reads

39Profile Views

Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?

Am Soc Clin Oncol Educ Book 2018 May;38:280-291

From the Royal Marsden Hospital, London, United Kingdom; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Royal Marsden Hospital, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_200785DOI Listing
May 2018

Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.

Ann Nucl Med 2018 Apr 13;32(3):165-174. Epub 2018 Jan 13.

Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12149-018-1229-0DOI Listing
April 2018

Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).

J Clin Oncol 2017 Nov 4;35(32):3671-3677. Epub 2017 Oct 4.

Charles S. Fuchs, Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Charles S. Fuchs, Peter C. Enzinger, Jeffrey Meyerhardt, and Robert J. Mayer, Dana-Farber/Partners CancerCare; Harvey J. Mamon and Richard S. Swanson, Brigham and Women's Hospital, Boston, MA; Donna Niedzwiecki and Xing Ye, Alliance Statistics and Data Center, Duke University; Christopher G. Willett, Duke Cancer Institute, Duke University Medical Center, Durham; Joel E. Tepper, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Daniel G. Haller, University of Pennsylvania, Philadelphia, PA; Tomislav Dragovich, Banner MD Anderson Cancer Center, Gilbert; Leonard L. Gunderson, Mayo Clinic, Scottsdale, AZ; Steven R. Alberts, Mayo Clinic, Rochester, MN; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Richard M. Goldberg and Kristen Ciombor, Ohio State University, James Cancer Hospital, Columbus, OH; Alan P. Venook, University of California at San Francisco, San Francisco, CA; David Ilson and Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY; and David J. Berg, University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.2130
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.2130DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678342PMC
November 2017

A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy.

Patient Educ Couns 2017 Aug 22;100(8):1527-1536. Epub 2017 Mar 22.

McGraw Patterson Center for Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pec.2017.03.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492511PMC
August 2017

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

J Clin Oncol 2016 08 5;34(23):2736-42. Epub 2016 Jul 5.

Peter C. Enzinger and Robert J. Mayer, Dana-Farber Cancer Institute, Harvard Medical School, and Alliance for Clinical Trials in Oncology, Boston, MA; Barbara Ann Burtness and Steven J. Cohen, Fox Chase Cancer Center; Barbara Ann Burtness, Steven J. Cohen, and Al Bowen Benson III, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Philadelphia, PA; Donna Niedzwiecki, Xing Ye, and Kathe Douglas, Alliance Statistics and Data Center, Duke University, Durham, NC; David H. Ilson, Memorial Sloan Kettering Cancer Center and Alliance for Clinical Trials in Oncology, New York, NY; Victoria Meucci Villaflor, University of Chicago Medicine and Alliance for Clinical Trials in Oncology; Al Bowen Benson III, Northwestern University Feinberg School of Medicine, Chicago, IL; Alan Venook, University of California San Francisco Helen Diller Family Comprehensive Cancer Center and Alliance for Clinical Trials in Oncology, San Francisco, CA; and Richard M. Goldberg, Ohio State University James Comprehensive Cancer Center and Alliance for Clinical Trials in Oncology, Columbus, OH.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/06/30/JCO.2015.65
Web Search
http://dx.doi.org/10.1200/JCO.2015.65.5092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019745PMC
August 2016

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.

BMC Cancer 2016 07 13;16:468. Epub 2016 Jul 13.

Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://bmccancer.biomedcentral.com/articles/10.1186/s12885-0
Publisher Site
http://dx.doi.org/10.1186/s12885-016-2485-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944495PMC
July 2016

Rectal Cancer, Version 2.2015.

J Natl Compr Canc Netw 2015 Jun;13(6):719-28; quiz 728

Robert H. Lurie Comprehensive Cancer Center of Northwestern University; UCSF Helen Diller Family Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Vanderbilt-Ingram Cancer Center; City of Hope Comprehensive Cancer Center; Fox Chase Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Fred & Pamela Buffett Cancer Center; Mayo Clinic Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Alabama at Birmingham Comprehensive Cancer Center; Stanford Cancer Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Colorado Cancer Center; UC San Diego Moores Cancer Center; Roswell Park Cancer Institute; The University of Texas MD Anderson Cancer Center; Massachusetts General Hospital Cancer Center; Memorial Sloan Kettering Cancer Center; Huntsman Cancer Institute at the University of Utah; Moffitt Cancer Center; University of Michigan Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Duke Cancer Institute; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0087DOI Listing
June 2015

Prevalence and significance of subcentimeter hepatic lesions in patients with localized pancreatic adenocarcinoma.

Pract Radiat Oncol 2012 Oct-Dec;2(4):e89-e94. Epub 2012 Mar 31.

Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prro.2012.02.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350367PMC
March 2014

CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.

Virchows Arch 2007 May 20;450(5):529-37. Epub 2007 Mar 20.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-007-0398-3DOI Listing
May 2007

Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.

Clin Colorectal Cancer 2006 Sep;6(3):208-13

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CCC.2006.n.037DOI Listing
September 2006

A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus.

Cancer Invest 2006 Apr-May;24(3):229-34

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357900600633924DOI Listing
August 2006

A Phase II trial of gemcitabine for metastatic neuroendocrine tumors.

Cancer 2004 Sep;101(5):934-9

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.20466DOI Listing
September 2004

Colon cancer surgeries compared. In patients with certain characteristics, laparoscopically assisted colectomy works well.

Authors:
Peter C Enzinger

Health News 2004 Jul;10(7)

Dana Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
July 2004

Gastrointestinal cancer in older patients.

Semin Oncol 2004 Apr;31(2):206-19

Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
April 2004

Esophageal cancer.

N Engl J Med 2003 Dec;349(23):2241-52

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/abs/10.1056/NEJMra035010
Publisher Site
http://dx.doi.org/10.1056/NEJMra035010DOI Listing
December 2003

A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.

Cancer Invest 2003 ;21(4):505-11

Dana-Farber/Partners Cancer Care Gastrointestinal Cancer Center, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1081/cnv-120022359DOI Listing
October 2003